"Stem cell therapy is literally changing medicine today as we know it. Bioheart is thrilled to bring these treatments to patients all over the world who are currently suffering from debilitating diseases but who have limited treatment options." said Kristin Comella, Bioheart's Chief Scientific Officer.
The implantation occurred as a result of Bioheart's new partnership with Anosis Biomedical Limited to distribute Bioheart therapies to patients in the Middle East and surrounding areas. Azerbaijan is the largest country in the region located at the crossroads of Western Asia and Eastern Europe. Performed by Emrah Anar, M.D., Chief of Cardiology and Cardiovascular Surgery at Baku Central Military Hospital, a 55 year-old female patient with non-revascularized critical limb ischemia received the implantation.
The patient had critical limb ischemia with clinical presentation corresponding to Rutherford Categories 4 and Leriche-Fontaine Classification III and presented with rest pain, muscle wasting and thinning in the left leg. The left superficial femoral artery, popliteal artery and crural arteries were occluded and collateral arteries were very inadequate according to the patient's angiogram.
Adipose tissue was aspirated under local anesthesia with liposuction from the abdominal region. The stromal vascular fraction including mesenchymal stem cells was derived from the patient's adipose tissue and mixed with platelet rich plasma (PRP) from the patient. The mixture was injected into the muscle tissue below the knee and the procedure was completed without complications.
Critical limb ischemia is a severe blockage in the arteries of the lower extremities, which markedly reduces blood-flow. It is a serious form of peripheral arterial disease (PAD). PAD is caused by atherosclerosis, the hardening and narrowing of the arteries over time due to the buildup of fatty deposits called plaque.